Plant Name: Fibraurea recisa
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| DRD5; HTR1A; DRD3; DRD4; DRD1; DRD2; | |
| BCHE; GAA; ACHE; | |
| HIF1A; | |
| F3; SIGMAR1; LMNA; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Small molecule receptor (family A GPCR) | DRD5 | Dopamine D5 receptor | P21918 | CHEMBL1850 |
| Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
| Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
| Unclassified | SIGMAR1 | Sigma opioid receptor | Q99720 | CHEMBL287 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0035240; dopamine binding | 6.650E-13 | 4.827E-09 | DRD1, DRD2, DRD3, DRD4, DRD5 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.001E-11 | 4.361E-08 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0001975; response to amphetamine | 3.372E-11 | 9.179E-08 | DRD1, DRD2, DRD3, DRD4, DRD5 |
| BP | GO:0007610; behavior | GO:0048148; behavioral response to cocaine | 3.207E-09 | 3.174E-06 | DRD1, DRD2, DRD3, DRD4 |
| MF | GO:0060089; molecular transducer activity | GO:0001591; dopamine neurotransmitter receptor activity, coupled via Gi/Go | 4.504E-08 | 2.885E-05 | DRD2, DRD3, DRD4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 7.135E-08 | 4.143E-05 | BCHE, CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0007191; adenylate cyclase-activating dopamine receptor signaling pathway | 9.640E-08 | 4.404E-05 | DRD1, DRD3, DRD5 |
| BP | GO:0009987; cellular process | GO:0007195; adenylate cyclase-inhibiting dopamine receptor signaling pathway | 9.640E-08 | 4.404E-05 | DRD2, DRD3, DRD4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 9.709E-08 | 4.404E-05 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0007610; behavior | GO:0008542; visual learning | 1.266E-07 | 5.511E-05 | DRD1, DRD2, DRD3, HIF1A |
| BP | GO:0050896; response to stimulus | GO:0034776; response to histamine | 1.325E-07 | 5.551E-05 | DRD2, DRD3, DRD4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.765E-07 | 6.864E-05 | CYP1A2, CYP2C19, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.765E-07 | 6.864E-05 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0060134; prepulse inhibition | 2.293E-07 | 8.323E-05 | DRD1, DRD2, DRD3 |
| BP | GO:0009987; cellular process | GO:0060158; phospholipase C-activating dopamine receptor signaling pathway | 2.293E-07 | 8.323E-05 | DRD1, DRD2, DRD5 |
| BP | GO:0008152; metabolic process | GO:0042053; regulation of dopamine metabolic process | 7.741E-07 | 2.516E-04 | DRD1, DRD4, HTR1A |
| BP | GO:0007610; behavior | GO:0046960; sensitization | 9.167E-07 | 2.811E-04 | DRD1, DRD5 |
| MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 9.167E-07 | 2.811E-04 | ACHE, BCHE |
| BP | GO:0051179; localization | GO:0050482; arachidonic acid secretion | 1.411E-06 | 4.153E-04 | DRD2, DRD3, DRD4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.411E-06 | 4.153E-04 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 2.748E-06 | 6.959E-04 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0060160; negative regulation of dopamine receptor signaling pathway | 2.748E-06 | 6.959E-04 | DRD2, DRD3 |
| BP | GO:0023052; signaling | GO:0051586; positive regulation of dopamine uptake involved in synaptic transmission | 2.748E-06 | 6.959E-04 | DRD2, DRD4 |
| BP | GO:0007610; behavior | GO:0001662; behavioral fear response | 3.221E-06 | 7.742E-04 | DRD1, DRD4, HTR1A |
| BP | GO:0065007; biological regulation | GO:0007194; negative regulation of adenylate cyclase activity | 3.930E-06 | 8.915E-04 | DRD2, DRD3, DRD4 |
| CC | GO:0043226; organelle | GO:0097730; non-motile cilium | 3.930E-06 | 8.915E-04 | DRD1, DRD2, DRD5 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 4.736E-06 | 1.052E-03 | CYP2C19, CYP2D6, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0001588; dopamine neurotransmitter receptor activity, coupled via Gs | 5.494E-06 | 1.161E-03 | DRD1, DRD5 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.494E-06 | 1.161E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 6.601E-06 | 1.343E-03 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0045776; negative regulation of blood pressure | 9.041E-06 | 1.779E-03 | DRD2, DRD3, DRD5 |
| BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 9.151E-06 | 1.779E-03 | DRD1, DRD2 |
| BP | GO:0040011; locomotion | GO:0090325; regulation of locomotion involved in locomotory behavior | 9.151E-06 | 1.779E-03 | DRD2, DRD3 |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 1.230E-05 | 2.195E-03 | DRD1, DRD2, DRD3, DRD4, DRD5, F3, HTR1A, SIGMAR1 |
| BP | Unclassified; | GO:0032415; regulation of sodium:proton antiporter activity | 1.372E-05 | 2.334E-03 | DRD3, DRD4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.595E-05 | 2.535E-03 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0042165; neurotransmitter binding | 1.730E-05 | 2.729E-03 | ACHE, BCHE, HTR1A |
| BP | GO:0065007; biological regulation | GO:0006874; cellular calcium ion homeostasis | 2.692E-05 | 3.909E-03 | DRD1, DRD2, DRD3, DRD4, DRD5 |
| BP | GO:0032501; multicellular organismal process | GO:0030432; peristalsis | 4.106E-05 | 5.485E-03 | DRD1, DRD2 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.106E-05 | 5.485E-03 | CYP1A2, CYP2C19 |
| BP | GO:0032501; multicellular organismal process | GO:0007416; synapse assembly | 4.237E-05 | 5.591E-03 | ACHE, DRD1, DRD2 |
| BP | GO:0009987; cellular process | GO:0002031; G-protein coupled receptor internalization | 5.015E-05 | 6.424E-03 | DRD2, DRD3 |
| BP | GO:0032502; developmental process | GO:0021756; striatum development | 5.015E-05 | 6.424E-03 | DRD1, DRD2 |
| MF | Unclassified; | GO:0004872; receptor activity | 5.841E-05 | 7.248E-03 | DRD1, DRD2, DRD3, DRD4, DRD5, F3, HTR1A, SIGMAR1 |
| BP | GO:0007610; behavior | GO:0007625; grooming behavior | 6.015E-05 | 7.358E-03 | DRD1, DRD2 |
| CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 6.015E-05 | 7.358E-03 | SMN1, SMN2 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 6.161E-05 | 7.412E-03 | DRD1, DRD2, DRD3, HIF1A |
| BP | GO:0051179; localization | GO:1904063; negative regulation of cation transmembrane transport | 7.054E-05 | 8.228E-03 | DRD2, DRD3, DRD4 |
| BP | GO:0051179; localization | GO:0002028; regulation of sodium ion transport | 7.054E-05 | 8.228E-03 | DRD2, DRD3, DRD4 |
| BP | GO:0032501; multicellular organismal process | GO:0035815; positive regulation of renal sodium excretion | 7.104E-05 | 8.228E-03 | DRD2, DRD3 |
| CC | GO:0044422; organelle part | GO:0060170; ciliary membrane | 7.054E-05 | 8.228E-03 | DRD1, DRD2, DRD5 |
| CC | GO:0032991; macromolecular complex | GO:0032797; SMN complex | 7.104E-05 | 8.228E-03 | SMN1, SMN2 |
| CC | GO:0016020; membrane | GO:0031090; organelle membrane | 8.120E-05 | 9.209E-03 | CYP1A2, CYP2C19, CYP2D6, CYP3A4, DRD1, DRD2, DRD5, GAA, LMNA, SIGMAR1 |
| BP | GO:0007610; behavior | GO:0048149; behavioral response to ethanol | 8.283E-05 | 9.345E-03 | DRD2, DRD4 |
| BP | GO:0008152; metabolic process | GO:0042133; neurotransmitter metabolic process | 8.398E-05 | 9.427E-03 | ACHE, BCHE, HTR1A |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.117E-07 | 3.508E-06 | DRD1; DRD2; DRD3; DRD4; DRD5 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.559E-07 | 3.508E-06 | HTR1A; DRD1; DRD2; DRD3; DRD4; DRD5 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 4.835E-07 | 7.253E-06 | CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.615E-06 | 2.942E-05 | CYP1A2; CYP3A4; CYP2C19 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 3.279E-05 | 2.951E-04 | HTR1A; DRD1; DRD2; DRD5 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.335E-05 | 3.251E-04 | CYP2D6; CYP1A2; CYP3A4 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.552E-04 | 8.729E-04 | CYP2D6; HTR1A; CYP2C19 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 6.139E-05 | 3.946E-04 | CYP1A2; CYP3A4; CYP2C19 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 9.791E-04 | 4.896E-03 | DRD1; DRD2 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.716E-03 | 7.021E-03 | CYP1A2; CYP3A4 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.369E-03 | 6.162E-03 | CYP1A2; CYP3A4 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 3.118E-03 | 1.169E-02 | DRD1; DRD2 |
| hsa05012 | Parkinson's disease_Homo sapiens_hsa05012 | 7.908E-03 | 2.542E-02 | DRD1; DRD2 |
| hsa03013 | RNA transport_Homo sapiens_hsa03013 | 1.142E-02 | 3.297E-02 | SMN2; SMN1 |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 1.246E-02 | 3.297E-02 | DRD1; DRD5 |
| hsa05034 | Alcoholism_Homo sapiens_hsa05034 | 1.232E-02 | 3.297E-02 | DRD1; DRD2 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.741E-03 | 1.641E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR1A; CYP2D6 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | DRD2 |
| NA: NA | False perceptions | NA | DRD2 |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2 |
| NA: NA | Corneal vascularity | NA | DRD2 |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | HTR1A; HTR1A; DRD2; ACHE; ACHE; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR1A; CYP3A4; DRD2; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2 |
| NA: NA | Hyperaemia | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | DRD3; HTR1A |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2 |
| NA: NA | Peripheral sensory neuropathies | NA | HTR1A |
| NA: NA | Peripheral vasoconstriction | NA | DRD2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | HTR1A |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD3; DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2 |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2 |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; ACHE |
| NA: NA | Bulimia nervosa | NA | HTR1A |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | HTR1A |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | DRD5; HIF1A |
| NA: NA | Social phobia | NA | HTR1A |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR1A |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1A; HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | DRD2 |
| NA: NA | Episode | NA | HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; DRD2; DRD2; DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD3; DRD4; DRD5; HTR1A; HTR1A; DRD1; DRD2; DRD2; DRD2; DRD2 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| C00-D49: Neoplasms | Breast cancer | C50 | DRD2 |
| NA: NA | Schizoaffective disorder | NA | HTR1A |
| NA: NA | Anxiety disorders | NA | HTR1A |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | DRD2 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | HTR1A; DRD1; DRD2; ACHE |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | F3 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | HTR1A; DRD1; DRD2; ACHE |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD3; DRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | HTR1A; DRD1; ACHE |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | HTR1A; DRD1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2 |
| NA: NA | Cervical dystonia | NA | HTR1A |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD3; DRD4; HTR1A; DRD1; DRD2 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3 |
| NA: NA | Itching | NA | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | DRD2 |
| NA: NA | Inflammatory diseases | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; DRD2 |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | HTR1A |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2 |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR1A |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| NA: NA | Schizoaffective disorders | NA | DRD2 |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A |
| NA: NA | Vomiting | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR1A; HTR1A |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2 |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1 |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2 |
| NA: NA | Malignant essential hypertension | NA | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | DRD2; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR1A; HTR1A; DRD2 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | HTR1A; DRD1; DRD2; DRD2 |